Alvotech (NASDAQ:ALVO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Alvotech to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, dividends, earnings and risk.
Analyst Ratings
This is a summary of recent ratings and price targets for Alvotech and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alvotech | 1 | 1 | 5 | 0 | 2.57 |
| Alvotech Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Alvotech presently has a consensus target price of $8.40, indicating a potential upside of 103.88%. As a group, “Biotechnology” companies have a potential upside of 114.71%. Given Alvotech’s peers higher possible upside, analysts plainly believe Alvotech has less favorable growth aspects than its peers.
Earnings & Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Alvotech | $588.90 million | $27.92 million | -5.02 |
| Alvotech Competitors | $713.94 million | $9.18 million | -17.98 |
Alvotech’s peers have higher revenue, but lower earnings than Alvotech. Alvotech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Alvotech has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Alvotech’s peers have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Institutional and Insider Ownership
47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Alvotech and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alvotech | -50.62% | N/A | -11.71% |
| Alvotech Competitors | -12,519.20% | -215.47% | -31.42% |
Summary
Alvotech beats its peers on 8 of the 13 factors compared.
About Alvotech
Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
